Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 6631 AL 6645

Overview of Metformin and Neurodegeneration: A Comprehensive Review

Kruczkowska W, Gałęziewska J, Buczek P, Płuciennik E, Kciuk M, Śliwińska A.

Pharmaceuticals (Basel). 2025 Mar 28;18(4):486. doi: 10.3390/ph18040486.

Intersection of H(2)S and Nrf2 signaling: Therapeutic opportunities for neurodegenerative diseases

Soni P, Paswan S, Paul BD, Thomas B.

Neurotherapeutics. 2025 Oct;22(6):e00627. doi: 10.1016/j.neurot.2025.e00627. Epub 2025 Jun 21.

Copper homeostasis and cuproptosis: implications for neurodegenerative diseases

Tao F, Lin M, Meng X, Huang L, Zhuo B, Jiang S, Deng S, Meng Z, Shi J.

Front Aging Neurosci. 2025 Oct 13;17:1688554. doi: 10.3389/fnagi.2025.1688554. eCollection 2025.

CCR5 as a key modulator in neurocognitive disorders

Aung CTZ, Abuaqel K, Zhou M.

Exp Neurol. 2025 Dec;394:115450. doi: 10.1016/j.expneurol.2025.115450. Epub 2025 Aug 28.

Cell transplantation therapies in Huntington's disease - Current status and future directions

Guiloff AE, Barker RA.

Pharmacol Res. 2025 Dec;222:108025. doi: 10.1016/j.phrs.2025.108025. Epub 2025 Nov 4.

Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases

Feigin A, Evans EE, Fisher TL, Zauderer M.

Expert Opin Investig Drugs. 2025 Mar;34(3):109-119. doi: 10.1080/13543784.2025.2473055. Epub 2025 Mar 6.

Animal models of Huntington's disease. Pros and cons

Stepanova P, Voutilainen MH, Eriksson O, Lindholm D.

Brain Behav Immun Health. 2025 Dec 1;50:101149. doi: 10.1016/j.bbih.2025.101149. eCollection 2025 Dec.

Microglial immune memory in Parkinson's and Huntington's diseases: epigenetics, triggers, and therapies

Chowdhury R, Hendlinger A, Riess O, Schulze-Hentrich J.

Epigenomics. 2025 Aug;17(11):739-751. doi: 10.1080/17501911.2025.2518909. Epub 2025 Jul 1.

Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases

Meanti R, Bresciani E, Rizzi L, Molteni L, Coco S, Omeljaniuk RJ, Torsello A.

Biomed Pharmacother. 2025 May;186:118044. doi: 10.1016/j.biopha.2025.118044. Epub 2025 Apr 9.

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Emerging Therapies for Neurodegenerative Diseases

Chen P, Wang F, Ling B, Zhu Y, Lin H, Huang J, Wang X.

Int J Nanomedicine. 2025 Jul 2;20:8547-8565. doi: 10.2147/IJN.S526945. eCollection 2025.

Valbenazine for the treatment of chorea associated with Huntington's disease

Patino J, Furr Stimming E, Testa CM, Mehanna R.

Expert Opin Pharmacother. 2025 Feb;26(2):127-132. doi: 10.1080/14656566.2024.2445728. Epub 2024 Dec 30.

Dysfunctions of sleep and the circadian rhythm in Huntington's disease

Kaczmarska P, Rudzińska-Bar M.

Front Neurol. 2025 Nov 7;16:1693307. doi: 10.3389/fneur.2025.1693307. eCollection 2025.

Common alterations to astrocytes across neurodegenerative disorders

Derevyanko A, Tao T, Allen NJ.

Curr Opin Neurobiol. 2025 Feb;90:102970. doi: 10.1016/j.conb.2025.102970. Epub 2025 Jan 28.

Adenosine Receptors in Neuroinflammation and Neurodegeneration

Salmaso V, Menin S, Moro S, Spalluto G, Federico S.

Cells. 2025 Oct 11;14(20):1585. doi: 10.3390/cells14201585.

Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases

Choi Y, Chung WS.

Mol Neurodegener. 2025 Jul 9;20(1):81. doi: 10.1186/s13024-025-00870-9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias